Hemostatic and antifibrinolytic agent
PCP: Signs of shock or hypoperfusion, in association with an injury suggestive of occult or ongoing hemorrhage
PCP: Signs of shock or hypoperfusion in maternal vaginal bleeding >20 weeks or postpartum hemorrhage
PCP: Signs of shock or hypoperfusion in association with an injury suggestive of occult or ongoing hemorrhage
PCP: Signs of shock or hypoperfusion in maternal vaginal bleeding >20 weeks or postpartum hemorrhage
ACP: Signs of shock or hypoperfusion in association with an injury suggestive of occult or ongoing hemorrhage
Prevents clot degradation by competing for TPA receptor sites.
Intravenous:
May potentiate hypotension if administered too quickly
For intravenous use only. Do not administer intramuscularly or subcutaneously.